drugset / Trial / NCT03132571
Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the efficacy of combining open-label extended release bupropion (flexible dosing up to 450mg target) and naltrexone (37.5mg) versus Bupropion and placebo along with a daily 500 calorie reduction diet recommendation for weight and health risk reduction in 40 overweight/obese individuals with schizophrenia.
Timeline
- Start
- 2017-06-01
- Primary completion
- 2018-07-31
- Completion
- 2018-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naltrexone | Small molecule | 37.5 mg | Oral |
| Background | Bupropion | Small molecule | 450 mg | Oral |